

Amgen completed its acquisition of Immunex Corporation on July 15, 2002. This archived Immunex press releases is provided for reference only.

FOR IMMEDIATE RELEASE, October 16, 2001

New Appointments to Immunex Discovery Research Team

Thomas O. Daniel, M.D., Promoted to SVP, Discovery Research, Kendall Mohler, Ph.D., Promoted to VP, Biological Sciences

SEATTLE - Immunex Corporation (Nasdaq: IMNX) today announced the appointment of key researchers to lead its discovery research efforts. Thomas O. Daniel, M.D., has been promoted to senior vice president of discovery research and Kendall Mohler, Ph.D., has been promoted to vice president of biological sciences.

"Both Tom and Ken have made numerous contributions to Immunex and have been instrumental in broadening the research capabilities of our discovery research program," said Doug Williams, Ph.D., executive vice president and chief technology officer. "Positioning them at the helm of our discovery research team gives us the opportunity to build on their commitment and leadership supporting our drug development efforts."

In his newly appointed position, Dr. Daniel will be responsible for the oversight and integrative coupling of molecular discovery with preclinical therapeutic development. He will lead the biology and molecular biology groups. Dr. Mohler will take the lead to ensure coordination between the company's pre-clinical pipeline research and clinical and marketing efforts.

Prior to joining Immunex in 2000 as the vice president of oncology and vascular biology, Dr. Daniel was director of the Vanderbilt University Center for Vascular Biology and Professor of Medicine and Cell Biology. He received a B.A. in Chemistry from Southern Methodist University, Dallas, TX, and an M.D. from University of Texas Southwestern Medical School, Dallas, TX.

Joining Immunex in 1989, Dr. Mohler most recently served as senior director of the immunology department. In this capacity, he was responsible for pre-clinical research in the areas of transplantation, inflammation and autoimmunity. Additionally, he has lead the pre-clinical analysis of ENBREL® (etanercept), and has been studying the role of other TNF ligand family members in inflammation and autoimmune disease. He holds a Bachelor's degree in Biology from the University of Kansas, and received his Ph.D. in Immunology from the University of Texas Health Science Center in Dallas.

Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovations.

NOTE: Except for the historical information contained herein, this news release contains forward-looking statements that involve substantial risks and uncertainties. Among the factors that could cause actual results or timelines to differ materially are risks associated with research and clinical development, regulatory approvals, our supply capabilities and reliance on third-party manufacturers, product commercialization, competition, litigation and other risk factors listed from time to time in reports filed by Immunex with the SEC, including but not limited to risks described under the caption "Important Factors That May Affect Our Business, Our Results of Operations and Our Stock Price" within our most recently filed Form 10-Q. The forward-looking statements contained in this news release represent our judgment as of the date of this release. Immunex undertakes no obligation to publicly update any forward-looking statements. An electronic version of this news release -- as well as additional information about Immunex of interest to investors, customers, future employees and patients -- is available on the Immunex home page at www.immunex.com.

